4Matsuzaki, Differential expression of CCR5 and CRTH2 on infiltrated cells in muconsa of patients with ulcerative colitis [J]. J Gastroenterol Hepatol, 2003,18 ( 9 ):1081 - 1088.
5Inoue. characterization of cytokine expression in the rectal mucosal of ulcerative colitis [ J ]. correlation with disease activity, Am J Gastroenterol, 1994, (9) : 2441 - 2446.
2Ikeda Y, Akbar SM, Matsui H, Onji M. Antigen-presenting dendritic cells in ulcerative colitis. J Gastroenterol 2002;37(Suppl 14):53-55.
3Bamias G, Marini M, Moskaluk CA, Odashima M, Ross WG,Rivera-Nieves J, Cominelli F. Down-regulation of intestinal lymphocyte activation and Thl cytokine production by antibiotic therapy in a murine model of Crohn's disease. J Immunol 2002;169:5308-5314.
4Sawa Y, Oshitani N, Adachi K, Higuchi K, Matsumoto T,Arakawa T. Comprehensive analysis of intestinal cytokine messenger RNA profile by real-time quantitative polymerase chain reaction in patients with inflammatory bowel disease.Int J Mol Med 2003;11:175-179.
5Lakatos L. Immunology of inflammatory bowel diseases. Acta Physiol Hung 2000;87:355-372.
6Hata K, Andoh A, Sato H, Araki Y, Tanaka M, Tsujikawa T,Fujiyama Y, Bamba T. Sequential changes in luminal microflora and mucosal cytokine expression during developing of colitis in HLA-B27/beta2-microglobulin transgenic rats. Scand J Gastroenterol 2001;36:1185-1192.
7Sun FF, Lai PS, Yue G, Yin K, Nagele RG, Tong DM, Krzesicki RF, Chin JE, Wong PY. Pattern of cytokine and adhesion molecule mRNA in hapten- induced relapsing colon inflammation in the rat. Inflammation 2001;25:33-45.
8Sandborn WJ. Strategies for targeting tumour necrosis factor in IBD. Best Pract Res Clin Gastroenterol 2003;17:105-117.
9Su C, Salzberg BA, Lewis JD, Deren JJ, Kornbluth A, Katzka DA, Stein RB, Adler DR, Lichtenstein GR. Efficacy of antitumor necrosis factor therapy in patients with ulcerative colitis.Am J Gastroenterol 2002;97:2577-2584.
10Garrelds IM, Heiligers JP, Van Meeteren ME, Duncker DJ,Saxena PR, Meijssen MA, Zijlstra FJ.Interleukin-2-Deficient mice: effect on cytokines and inflammatory cells in chronic colonic disease. Dig Dis Sci 2002;47:503-510.
4De VRY C G, PRASAD S, KOMUVES L, et al. Non viral delivery onuclear factor-kappaB decoy ameliorates murine inflammatorbowel disease and restores tissue homeostasis[J]. Gut, 2007,56 : 524- 533.
5DUBUQUOY L, JANSSON E A, DEEB S, et al. Im- paired expression operoxisome proliferator-activated receptor gamma in ulcerativcolitis[J]. Gastroenterolo- gy,2003,124:1265 -1276.
6VOLKOV V L. Activity of the postanoids system in inflamma-49 [J]. Klin Khir, 2000,10 : 30- 31.
7CARTY E, MACEY M, MCCARTNEY S A, et al. Ri dogre. 1 A dual-thromboxane synthase inhibitor and re- ceptor antagonistanti-inflammatory profile in inflamma- tory bowel disease[J]. Aliment Pharmacol Ther, 2001, 14:807-810.
9Fan YY,Zhang WZ,Mulholl and M. Thrombin and PAR-1-APincrease proinfiammatory cytokine expression in C6 cells [J].The Journal of Surgical Research ,2005,129(2) :196-201.
